The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | The use of romidepsin, azacitidine, dexamethasone, and lenalidomide (RAdR) for T-cell lymphoma
Mark Roschewski, MD, NCI Center for Cancer Research, Bethesda, MD, talks on the use of romidepsin, azacitidine, dexamethasone, and lenalidomide (RAdR) for relapsed/refractory (R/R) T-cell lymphoma. This novel combination has achieved complete responses (CRs) in some patients, but these were not durable in the majority. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
